<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385111</url>
  </required_header>
  <id_info>
    <org_study_id>NCC-EUSEBUS</org_study_id>
    <nct_id>NCT01385111</nct_id>
  </id_info>
  <brief_title>Combined Application of EBUS and EUS in Lung Cancer</brief_title>
  <official_title>Combined Application of EBUS-TBNA and EUS-B-FNA in Mediastinal Staging of Lung Cancer; EBUS-TBNA Centered Procedure vs. EUS-B-FNA Centered Procedure, a Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate a diagnostic yield and performance characteristics according&#xD;
      to the order of endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA)&#xD;
      and endoscopic ultrasound-with bronchoscope-guided transbronchial needle aspiration&#xD;
      (EUS-B-FNA) in the mediastinal staging of potentially operable lung cancer. EUS-FNA is a&#xD;
      better tolerated procedure than EBUS-TBNA. Therefore, EUS-B-FNA can be the main procedure in&#xD;
      a combined approach with EBUS-TBNA and EUS-B-FNA. In group A, the investigators perform&#xD;
      EBUS-TBNA first and EUS-B-FNA is performed when necessary. In group B, EUS-B-FNA is first&#xD;
      applied and EBUS-TBNA is performed when necessary. The hypothesis is that the diagnostic&#xD;
      yield of the EUS centered procedure is as good as that of the EBUS centered procedure and the&#xD;
      EUS centered procedure is more tolerable than the EBUS centered procedure. We evaluate&#xD;
      diagnostic yields and performance characteristics of each group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy</measure>
    <time_frame>When the confimative disgnosis is available in all subjects (after surgery) ; 8-12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>During and just after the procedure ; 5-60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular measurement (change of blood pressure, changes of heart rate, number of patients with arrhythmia)</measure>
    <time_frame>During the procedure; 0-60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of desaturation</measure>
    <time_frame>During the procedure; 0-60minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discomfort by the procedure</measure>
    <time_frame>After the procedure ; 2-3hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse Events (infection, bleeding requiring intervention, pneumothorax, or any complications requiring hospital admission)</measure>
    <time_frame>During and after the procedure; 0-2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymph node features</measure>
    <time_frame>During and after the procedure; 0-2hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fentanyl/midazolam/lidocaine consumption</measure>
    <time_frame>After the procedure ; 1-2 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EBUS centered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EUS centered</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EUS-B-FNA followed by EBUS-TBNA</intervention_name>
    <description>EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EBUS-TBNA followed by EUS-B-FNA</intervention_name>
    <description>EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed or strongly suspected non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Potentially operable patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  M1 disease&#xD;
&#xD;
          -  Inoperable T4 disease&#xD;
&#xD;
          -  Mediastinal infiltration or extranodal invasion of the mediastinal lymph node visible&#xD;
             on chest CT.&#xD;
&#xD;
          -  Confirmed supraclavicular lymph node metastasis&#xD;
&#xD;
          -  Pancoast tumors&#xD;
&#xD;
          -  Medically inoperable patients&#xD;
&#xD;
          -  Contraindications for bronchoscopy and esophageal endoscopy&#xD;
&#xD;
          -  Drug reaction to lidocaine, midazolam,fentanyl&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Ground glass-dominant nodule ( &lt; 3cm)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin Hwangbo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Doctor, Senior Researcher</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center (NCC) Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2011</study_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2012</last_update_posted>
  <responsible_party>
    <name_title>Bin, Hwangbo</name_title>
    <organization>National Cancer center</organization>
  </responsible_party>
  <keyword>endobronchial ultrasound</keyword>
  <keyword>endoscopic ultrasound</keyword>
  <keyword>EBUS-TBNA</keyword>
  <keyword>EUS-FNA</keyword>
  <keyword>EUS-B-FNA</keyword>
  <keyword>lung cancer</keyword>
  <keyword>staging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

